Rein Therapeutics Inc. $RNTX Shares Bought by Voss Capital LP

Voss Capital LP grew its stake in Rein Therapeutics Inc. (NASDAQ:RNTX) by 86.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,666,532 shares of the company’s stock after purchasing an additional 1,232,846 shares during the period. Voss Capital LP owned about 10.14% of Rein Therapeutics worth $3,053,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BIOS Capital Management LP purchased a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $2,367,000. Cable Car Capital LP purchased a new stake in Rein Therapeutics during the second quarter worth $588,000. Vanguard Group Inc. grew its position in Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after buying an additional 284,300 shares during the period. Geode Capital Management LLC acquired a new stake in Rein Therapeutics during the second quarter valued at $344,000. Finally, Senvest Management LLC purchased a new position in Rein Therapeutics in the second quarter valued at $323,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Wall Street Analyst Weigh In

RNTX has been the subject of a number of analyst reports. Citigroup downgraded shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen cut Rein Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. Finally, Brookline Capital Acquisition downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Stock Performance

Shares of NASDAQ RNTX opened at $1.42 on Wednesday. The firm has a fifty day moving average of $1.23 and a 200 day moving average of $1.30. The firm has a market cap of $37.33 million, a PE ratio of -0.54 and a beta of 1.51. Rein Therapeutics Inc. has a one year low of $1.02 and a one year high of $2.40.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.